pfizer glp-1 agonist pulls out of race after safety concerns RCSB PDB - 7S15: GLP-1
Description
Originally developed and positioned as treatments for type 2 diabetes, these agents are now equally associated with weight management, reshaping how clinicians, patients, and pharmacies understand metabolic disease
Are they right for me
Glucagon-like peptide-1 receptor agonists, namely GLP-1 receptor agonists, are a class of drugs for the treatment of type 2 diabetes.
The glp-1 agonists market is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026 to 2032.
Premium Quality Supplements to Support Your Healthy Journey*
- Download as a PPTX, PDF or view online for free
